# Pyrotinib in HER2-positive Early Breast Cancer

> **NCT06718335** · NA · NOT_YET_RECRUITING · sponsor: **Nie Jianyun** · enrollment: 156 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Pyrotinib

## Key facts

- **NCT ID:** NCT06718335
- **Lead sponsor:** Nie Jianyun
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12-30
- **Primary completion:** 2027-12-30
- **Final completion:** 2029-12-30
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2024-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06718335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06718335, "Pyrotinib in HER2-positive Early Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06718335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*